ReviewFrontiers in cellular and infection microbiology2025
Post-liver transplantation bacterial infection: current status, prevention and treatment.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis - To Suppress or Not to Suppress?Alimentary pharmacology & therapeutics · 2026Review
- Multidrug resistant bacterial infection in liver transplant recipients: A Deterrent and obstacle.Pakistan journal of medical sciences · 2026Article
- Intuitive Risk Equation for Post-Transplant Bloodstream Infection Prediction: A Symbolic Regression Approach.Biomedicines · 2026Article
- Gut microbiota reconstruction after liver transplantation and its association with early postoperative infections in patients with liver failure.Frontiers in cellular and infection microbiology · 2026Article
- Drug-resistant bacterial infections in end-stage liver disease: immune imbalance and intervention advances.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation (LT) is one of the most effective treatments for end-stage liver disease, as evidenced by a 1-year survival rate of approximately 90% and a 5-year survival rate exceeding 70%. Bacterial infections not only are major complications affecting the quality of life and graft function of LT patients but also constitute the primary causes of morbidity and mortality in this population. Additionally, the rejection response following LT increases the need for postoperative immunosuppressive therapy, and because of the complexity of the immune response in both donors and recipients, LT recipients are more susceptible to bacterial infections than other postoperative patients are. Reports indicate that gram-negative bacteria (such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.